Professor Bobby Gaspar is to receive investment of up to £1million from the UCL Technology Fund (UCLTF) to support development of a gene therapy for familial haemophagocytic lymphohistiocytosis (FHL type 2 or ‘FHL-2’) through to a clinical trial.
Earlier this month patients and families at GOSH (Great Ormond Street Hospital) were given the chance to get hands-on with science at our Research Activity Trial and with special lessons in the hospital school.
The biopharmaceutical company Autolus has acquired global rights to develop and commercialize a novel T-cell therapy for the treatment of B-cell lymphomas and leukaemias.
The National Institute for Health Research (NIHR) GOSH Biomedical Research Centre (BRC) is part of a new £5 million consortium led by Kings College London which will strengthen London’s status as a world centre of commercialisation in medical technologies